Please assess the completion status of the following clinical trial:

Trial Title: A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient volunteered to participate in the study, and signed the Informed Consent~2. Age 18-70 years old, male or female~3. Patients with CD20+ DLBCL (including PMBCL and tFL), FL and MCL, at least one measurable lesion (LDi≥ 1.5 cm)~4. r/r lymphoma patients who received prior CD19 CAR-T therapy~5. At least one week from last treatment (radiation, chemotherapy, mAb, etc) to apheresis~6. No immunosuppressive therapy was used within 1 week before C-CAR066 infusion~7. No mAb treatment within 2 weeks before C-CAR066 infusion~8. Adequate organ and bone marrow function~9. No contraindications of apheresis~10. Expected survival time \> 3 months~11. ECOG scores 0-1~Exclusion Criteria:~1. Have a history of allergy to cellular products~2. Patients with cardiac insufficiency classified as Class III or IV according to the New York Heart Association (NYHA) Heart Function Classification Standard~3. A history of craniocerebral trauma, consciousness disorder, epilepsy, cerebral ischemia or hemorrhagic cerebrovascular disease~4. Patients with active CNS involvement~5. Patients with autoimmune disease, immunodeficiency, or other treatment requiring immunosuppressor~6. Severe active infection (except simple urinary tract, bacterial pharyngitis), or currently receiving intravenous antibiotics. However, prophylactic antibiotics, antiviral and antifungal treatments are allowed~7. Live vaccination within 4 weeks before apheresis~8. HIV, HBV, HCV and TPPA / RPR infections, and HBV carriers~9. Have a history of alcoholism, drug addiction and mental illness~10. Non-sterile subjects had any of the following: a) being pregnant / lactating; or b) having a pregnancy plan during the trial; or c) having fertility without taking effective contraception~11. Patients with severe fludarabine or cyclophosphamide hypersensitivity~12. The patient has a history of other primary cancers, except for the following:~    1. Non-melanoma such as skin basal cell carcinoma cured by resection~   2. Cured carcinoma in situ such as cervical, bladder or breast cancer~13. The investigators believe that there are other circumstances that are not suitable for the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- C-CAR066 (Type: EXPERIMENTAL): Autologous C-CAR066 (CD20-directed CAR T-cell) administered by intravenous (IV) infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).